• Home
  • Search Results
  • Stability of erythrocyte membrane and overall hemostasis potential - A biocompatibility study of mebrofenin and other iminodiacetic acid derivatives.

Stability of erythrocyte membrane and overall hemostasis potential - A biocompatibility study of mebrofenin and other iminodiacetic acid derivatives.

Pharmacological reports : PR (2015-10-21)
Magdalena Markowicz-Piasecka, Elżbieta Mikiciuk-Olasik, Joanna Sikora
ABSTRACT

Intravenous injection seems to be the most convenient way of administering drugs and contrast agents, which makes components of the blood the first and usually unwanted target of their action. Binding of intravenously administered compounds to erythrocytes, blood platelets and vascular wall may have serious clinical implications. The aim of this study was to examine the influence of four iminodiacetic acid derivatives, potential ligands for gadolinium complexation, on the process of coagulation and fibrinolysis, activity of thrombin and hemolysis. Kinetic parameters of coagulation and fibrinolysis process were determined during an optical CL-test based on measurement of transmittance alterations. Thrombin (0.5 IU/mL) and t-PA (240 ng/mL) were used to obtain a clotting and lysis curve. The activity of thrombin was determined with a chromogenic substrate S-2238. Hemolysis was examined spectrophotometrically and expressed as a percentage of released hemoglobin. Exposure to iminodiacetic acid derivatives resulted in a significant increase in the overall potential of clotting and lysis (CLAUC), as well as with the significant changes in the key parameters of these processes (thrombin time, initial plasma clotting velocity, clot stabilization time). Furthermore, iminodiacetic acid derivatives caused a significant decrease in the amidolytic activity of thrombin and enhanced hemolysis in a concentration-dependent manner. Despite their influence on the process of coagulation and fibrinolysis, amidolytic activity of thrombin and hemolysis, iminodiacetic acid derivatives should be generally considered safe as the significant effects were observed mostly at 4 μmol/mL, which is about 10-fold higher than the theoretical plasma concentration of these compounds.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pyridine, anhydrous, 99.8%
Sigma-Aldrich
Acetic anhydride, ReagentPlus®, ≥99%
Sigma-Aldrich
Acetic anhydride, ACS reagent, ≥98.0%
Sigma-Aldrich
Pyridine, ACS reagent, ≥99.0%
Sigma-Aldrich
Acetic anhydride, 99.5%
Sigma-Aldrich
Nitrilotriacetic acid, Sigma Grade, ≥99%
Sigma-Aldrich
p-Toluidine, 99.6%
Sigma-Aldrich
Iminodiacetic acid, 98%
Sigma-Aldrich
Acetic anhydride, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
Pyridine, ReagentPlus®, ≥99%
Sigma-Aldrich
2,4,6-Trimethylaniline, 98%
Sigma-Aldrich
Pyridine, ≥99%
Sigma-Aldrich
p-Toluidine, 99%
Sigma-Aldrich
Nitrilotriacetic acid, ACS reagent, ≥99.0%
Sigma-Aldrich
Pyridine, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
2,4-Dimethylaniline, ≥99%
Supelco
2,4-Dimethylaniline, analytical standard
Sigma-Aldrich
Pyridine, biotech. grade, ≥99.9%
Sigma-Aldrich
Tris(tert-butoxy)silanol, 99.999%
Sigma-Aldrich
2,4-Dimethylaniline, 98%
Sigma-Aldrich
Nitrilotriacetic acid, BioUltra, ≥99.0% (T)
Sigma-Aldrich
Pyridine, ReagentPlus®, ≥99%
Sigma-Aldrich
Pyridine, ACS reagent, ≥99.0%
Sigma-Aldrich
Acetic anhydride, Lonza quality, ≥99.5% (GC)
Sigma-Aldrich
Tris(tert-butoxy)silanol, packaged for use in deposition systems
Sigma-Aldrich
Acetic anhydride

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.